A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The phase II clinical study is to investigate the safety, tolerability, efficacy and
pharmacokinetics of ICP-022.
Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with
R/R MZL will be evaluated in approximately 80 subjects. Pharmacokinetics of ICP-022 will be
evaluated in approximately 20 subjects.